Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US10179817B2
Publication/Patent Number: US10179817B2
Publication date: 2019-01-15
Application number: 15/146,294
Filing date: 2016-05-04
Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic ...more ...less
2
US10179172B2
Publication/Patent Number: US10179172B2
Publication date: 2019-01-15
Application number: 14/483,880
Filing date: 2014-09-11
Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes. Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations ...more ...less
3
US10179174B2
Publication/Patent Number: US10179174B2
Publication date: 2019-01-15
Application number: 14/122,238
Filing date: 2012-05-24
Assignee: Cel-Sci Corp.
Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P1-x-P2, where P2 is a peptide associated with an infectious agent and P1 is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent. Dyes, radioisotopes, or therapeutic agents conjugated with the dendritic cells can be used for localization of the immune target and/or prophylactic or therapeutic treatment of the disease. The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions ...more ...less
4
US10213409B2
Publication/Patent Number: US10213409B2
Publication date: 2019-02-26
Application number: 15/141,170
Filing date: 2016-04-28
Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
5
US10232040B2
Publication/Patent Number: US10232040B2
Publication date: 2019-03-19
Application number: 14/710,101
Filing date: 2015-05-12
Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
6
US10232051B2
Publication/Patent Number: US10232051B2
Publication date: 2019-03-19
Application number: 15/448,639
Filing date: 2017-03-03
Inventor: Zhao, Robert Yongxin  
Abstract: Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided.
7
US10222386B2
Publication/Patent Number: US10222386B2
Publication date: 2019-03-05
Application number: 15/511,860
Filing date: 2015-09-18
Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control. The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method ...more ...less
8
US10279035B2
Publication/Patent Number: US10279035B2
Publication date: 2019-05-07
Application number: 15/412,536
Filing date: 2017-01-23
Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof. This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity) ...more ...less